Paratracheal lymph node dissection during total (pharyngo-)laryngectomy: A systematic review and meta-analysis.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
09 2022
Historique:
received: 02 06 2022
revised: 20 06 2022
accepted: 05 07 2022
pubmed: 14 7 2022
medline: 27 7 2022
entrez: 13 7 2022
Statut: ppublish

Résumé

The objective of this review was to determine the rate and risk factors of paratracheal lymph node (PTLN) involvement during total laryngectomy (TL) or total pharyngolaryngectomy (TPL). In addition, we aimed to assess its prognostic significance in terms of survival and peristomal recurrence. A comprehensive electronic search was performed on PubMed, EMBASE, and CENTRAL databases. We searched for studies reporting outcomes of PTLN dissection during radical laryngeal surgery for squamous cell carcinoma of the larynx, hypopharynx or cervical oesophagus. We included a total of ten studies (838 patients). The overall rate of PTLN dissection positivity was 18.6% (20.7% for primary TL, 8.7% for salvage TL). Random-effects meta-analysis identified T4 stage, N+ stage of the lateral neck, subglottis involvement and primary tumour arising from the hypopharynx or cervical oesophagus as significant risk factors for PTLN involvement. This meta-analysis allowed to better define the risk of PTLN involvement during TL or TPL, in a bid to guide indication for PTLN dissection. There is a need for further large studies reporting rigorously the outcomes of PTLN dissection in order to establish stronger evidence-based recommendations.

Identifiants

pubmed: 35830760
pii: S1368-8375(22)00306-2
doi: 10.1016/j.oraloncology.2022.106017
pii:
doi:

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

106017

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Auteurs

Emilien Chabrillac (E)

Department of Surgery, University Cancer Institute of Toulouse - Oncopole, Toulouse, France; Department of Ear, Nose & Throat Surgery, Toulouse University Hospital - Larrey Hospital, Toulouse, France. Electronic address: emilien.chabrillac@gmail.com.

Richard Jackson (R)

Department of Ear, Nose & Throat Surgery, Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK.

Pierre Mattei (P)

Department of Surgery, University Cancer Institute of Toulouse - Oncopole, Toulouse, France; Department of Ear, Nose & Throat Surgery, Toulouse University Hospital - Larrey Hospital, Toulouse, France.

Grégoire D'Andréa (G)

Department of Ear, Nose & Throat Surgery, University Institute of the Face and Neck, Nice, France.

Sébastien Vergez (S)

Department of Surgery, University Cancer Institute of Toulouse - Oncopole, Toulouse, France; Department of Ear, Nose & Throat Surgery, Toulouse University Hospital - Larrey Hospital, Toulouse, France.

Agnès Dupret-Bories (A)

Department of Surgery, University Cancer Institute of Toulouse - Oncopole, Toulouse, France; Department of Ear, Nose & Throat Surgery, Toulouse University Hospital - Larrey Hospital, Toulouse, France.

Ovie Edafe (O)

Oncology & Metabolism, University of Sheffield, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH